Veracyte: Profitable, De-Risked, And Ready To Run
Veracyte (VCYT) has transitioned to a profitable, diversified model with strong operating leverage and self-fortifying balance sheet. Key 2025-2026 catalysts include deeper prostate cancer penetration, entry into minimal residual disease, and U.S. re-launch of the Prosigna breast cancer test. VCYT projects 16% revenue growth to $515–$517M in FY25 and >25% adjusted EBITDA margin, signaling sustained profitable execution.
Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Is This the Right Time to Add Veracyte Stock to Your Portfolio?
VCYT's Afirma and Decipher fuel strong test volume growth and a debt-free balance sheet, but rising macro costs and expenses temper the outlook.
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up
Veracyte surges 27.5% after Q3 earnings and revenues beat estimates, driven by strong Decipher and Afirma test growth.
Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript
Veracyte, Inc. ( VCYT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO John Leite - Global Chief Commercial Officer Phillip Febbo - Chief Scientific & Medical Officer Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Puneet Souda - Leerink Partners LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Lu Li - UBS Investment Bank, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Benjamin Mee - Stephens Inc., Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Good day, and thank you for standing by.
Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.19 per share a year ago.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Veracyte: Q2 Earnings Brings My Position Out Of Mothballs
Veracyte's Q2 results show strong revenue growth, margin expansion, and a robust cash position, reinforcing my long-term bullish outlook. Key growth drivers include Decipher's expansion, upcoming product launches, and a pipeline of catalysts through 2028 supporting sustained revenue increases. Risks remain: high valuation, competitive pressures, and reimbursement uncertainties could lead to volatility or margin compression if growth falters.
Is the Options Market Predicting a Spike in Veracyte Stock?
Investors need to pay close attention to VCYT stock based on the movements in the options market lately.
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Veracyte (VCYT) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
